268 related articles for article (PubMed ID: 11527081)
41. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
42. Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.
Roemmler J; Bidlingmaier M; Schopohl J
Pituitary; 2010; 13(1):89-93. PubMed ID: 18498055
[TBL] [Abstract][Full Text] [Related]
43. Metabolic effects of GH antagonism in patients with acromegaly.
Trainer PJ
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
[TBL] [Abstract][Full Text] [Related]
44. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly.
Morrison KM; Wu Z; Bidlingmaier M; Strasburger CJ
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S61-3. PubMed ID: 11527090
[TBL] [Abstract][Full Text] [Related]
45. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
46. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
47. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
48. The role of growth hormone-receptor antagonism in relation to acromegaly.
Ayuk J; Sheppard MC
Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
[TBL] [Abstract][Full Text] [Related]
49. Long-term effects of pegvisomant in patients with acromegaly.
Hodish I; Barkan A
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
[TBL] [Abstract][Full Text] [Related]
50. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.
Drake WM; Berney DM; Kovacs K; Monson JP
Eur J Endocrinol; 2005 Aug; 153(2):203-5. PubMed ID: 16061824
[TBL] [Abstract][Full Text] [Related]
51. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological therapy for acromegaly: a critical review.
Muller AF; Van Der Lely AJ
Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
[TBL] [Abstract][Full Text] [Related]
53. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
54. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
[TBL] [Abstract][Full Text] [Related]
55. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
56. Experience from the German pegvisomant observational study.
Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
[TBL] [Abstract][Full Text] [Related]
57. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
58. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
59. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
60. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]